APO-Pemetrexed pemetrexed 500 mg (as disodium) powder for injection vial

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

pemetrexed disodium hemipentahydrate, Quantity: 604 mg (Equivalent: pemetrexed, Qty 500 mg)

Pieejams no:

Arrotex Pharmaceuticals Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

pemetrexed disodium hemipentahydrate

Zāļu forma:

Injection, powder for

Kompozīcija:

Excipient Ingredients: sodium hydroxide; hydrochloric acid; mannitol

Ievadīšanas:

Intravenous Infusion

Vienības iepakojumā:

1

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Produktu pārskats:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorizācija statuss:

Registered

Autorizācija datums:

2014-09-04